We’re less than two days away from the official opening of IAS 2021 – the 11th IAS Conference on HIV Science. If you have not yet registered as media, it’s not too late to gain full access to the conference – register now!
In this advisory:
- Abstract embargo information
- Opening session and panel info, for Sunday, 18 July
- Updated media summary for Abstract 2585
Abstract posting and embargoes
on-demand abstracts and e-posters will be available and their embargo lifts from Saturday, 17 July, at 12:00 (noon) CEST.
- Scheduled sessions will start on Sunday, 18 July, at 07:30 CEST.
the official opening of IAS 2021
The session includes a panel discussion, “From Pandemic to Pandemic”, featuring:
- Anthony Fauci, National Institutes of Health, United States
Raphael, Advocacy for the Prevention of HIV and AIDS, United States
- Soumya Swaminathan, World Health Organization, Switzerland
- Jens Spahn, Federal Minister of Health, Germany
Updated media summary: Prevalence of HIV drug resistance in PrEP rollout participants who acquire HIV, Abstract 2585
The following is an updated summary of Abstract 2585, which is related to the prevalence
of HIV drug resistance in PrEP rollout participants who acquire HIV. It was featured in the IAS 2021 official press conference and news release, and has been updated to include new data and information from the author.
from the Global Evaluation of Microbicide Sensitivity (GEMS) project found very low rates of seroconversion among individuals participating in HIV pre-exposure prophylaxis (PrEP) rollout programmes in sub-Saharan Africa. In the small subset of individuals
who acquired HIV despite being in a PrEP programme, 23% were found to have HIV with resistance mutations to the antiretroviral drugs used for PrEP.
The project implemented drug resistance monitoring for PrEP users
who were diagnosed with HIV during participation in oral TDF-based PrEP programmes in Eswatini, Kenya, South Africa and Zimbabwe. Of the estimated 104,000 PrEP users, 229 seroconversions were reported and 208 participants provided a sample
for the study. Half of participants were 16-24 years of age and three-quarters were female. The majority were on PrEP from more than three months before becoming HIV positive.
Of the 118 samples successfully genotyped, 44% had at
least one HIV drug resistance mutation. Most of the resistance mutations were unrelated to PrEP use; that is, they had originated from antiretroviral therapy in the partner who transmitted HIV. Only one-fifth of the samples had mutations associated
with the drugs used for PrEP, with the majority (23 of 27 cases) due to the emtricitabine/FTC mutation, M184I/V. There were only four cases of tenofovir-resistant HIV. Fortunately, recent studies have shown that HIV with the M184V/I mutations and/or tenofovir-associated
mutations can be effectively treated with widely available combinations of antiretroviral drugs that are in the form of one pill taken daily.
“Taking PrEP every day is very effective at preventing HIV,” Dr Urvi Parikh,
Associate Professor of Medicine at the University of Pittsburgh and Co-Director of the GEMS study, said. “The number of reported infections on PrEP was very small compared to the number of PrEP users, which tells us that the benefit
of PrEP in preventing HIV far outweighs the risk of drug resistance.” Continued monitoring for drug resistance with PrEP rollout will be important for the long-term success of both treatment and prevention programmes.